意外BD，炸出新潜力靶点

Core Insights - Changchun High-tech announced a collaboration with Yarrow Bioscience for the GenSci098 pipeline, which includes an upfront payment of $120 million and potential milestone payments totaling up to $1.365 billion, along with over 10% royalties on net sales [1] Group 1: Financial Aspects - The agreement includes a non-refundable upfront payment of $70 million and a subsequent milestone payment of $50 million [1] - The total potential milestone payments could reach $1.365 billion, indicating significant future revenue potential for the company [1] Group 2: Product and Target Information - GenSci098 targets the TSH receptor (TSHR), which is involved in the hypothalamic-pituitary-thyroid (HPT) axis and is crucial for regulating thyroid hormone levels [2][3] - The drug is aimed at treating Graves' disease, an autoimmune condition characterized by the overproduction of thyroid hormones due to TSH receptor antibodies [4][6] Group 3: Competitive Landscape - K1-70 was a previous TSHR monoclonal antibody that entered clinical trials but was discontinued for unspecified reasons, indicating challenges in this therapeutic area [6][7] - Other companies like IMVT and Viridian Therapeutics are also developing treatments targeting similar pathways, with IMVT focusing on a next-generation pipeline [9][11] Group 4: Market Potential - If GenSci098 proves successful in treating Graves' disease and thyroid eye disease (TED), it could potentially achieve sales figures comparable to Tepezza, which has around $2 billion in sales [12]